Kura Oncology (NASDAQ:KURA) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research note published on Friday morning, Benzinga reports. HC Wainwright currently has a $32.00 price objective on the stock.

KURA has been the subject of a number of other reports. Wedbush restated an outperform rating and issued a $37.00 price objective on shares of Kura Oncology in a research report on Friday. JMP Securities boosted their price target on shares of Kura Oncology from $22.00 to $32.00 and gave the stock a market outperform rating in a report on Wednesday, January 31st. Finally, StockNews.com lowered shares of Kura Oncology from a hold rating to a sell rating in a research report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $28.28.

Kura Oncology Price Performance

KURA opened at $21.01 on Friday. The company has a current ratio of 16.67, a quick ratio of 16.67 and a debt-to-equity ratio of 0.02. The firm has a fifty day moving average price of $20.66 and a 200 day moving average price of $16.13. Kura Oncology has a 1 year low of $7.41 and a 1 year high of $24.17.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Thursday, May 2nd. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.03). During the same period last year, the firm earned ($0.50) EPS. The firm’s revenue was up .0% on a year-over-year basis. On average, research analysts anticipate that Kura Oncology will post -2.35 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of KURA. BVF Inc. IL increased its holdings in shares of Kura Oncology by 9.5% in the fourth quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock valued at $106,027,000 after purchasing an additional 642,245 shares during the last quarter. Deerfield Management Company L.P. Series C increased its stake in shares of Kura Oncology by 35.1% in the 3rd quarter. Deerfield Management Company L.P. Series C now owns 4,374,044 shares of the company’s stock worth $39,891,000 after acquiring an additional 1,136,044 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Kura Oncology by 7.5% during the 3rd quarter. Vanguard Group Inc. now owns 3,924,448 shares of the company’s stock worth $35,791,000 after acquiring an additional 275,173 shares during the period. Armistice Capital LLC boosted its position in shares of Kura Oncology by 5.3% during the 3rd quarter. Armistice Capital LLC now owns 2,236,000 shares of the company’s stock valued at $20,392,000 after acquiring an additional 112,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Kura Oncology by 10.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,001,754 shares of the company’s stock valued at $28,785,000 after purchasing an additional 197,530 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.